The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2018 | Treatment sequencing in multiple myeloma: a multitude of options
Heinz Ludwig, MD, PhD, from Wilhelminen Cancer Research Institute, Vienna, Austria, discusses treatment sequencing in multiple myeloma (MM). Dr Ludwig covers the many options available to treat MM, particularly when options are restricted in cases of drug resistance and relapse. This interview took place at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
